These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 11868872

  • 1. Systemic hypersensitivity reaction to mesacol.
    Sule A, Gaitonde S, Bhojani K, Mittal G, Balakrishnan C, Gurmeet M, Deshpande RB, Joshi VR.
    J Assoc Physicians India; 2001 Nov; 49():1120-2. PubMed ID: 11868872
    [No Abstract] [Full Text] [Related]

  • 2. Reversal reaction occurring 16 years after beginning antibacterial treatment.
    Rea TH.
    Lepr Rev; 2004 Mar; 75(1):86-90. PubMed ID: 15072130
    [No Abstract] [Full Text] [Related]

  • 3. Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis.
    Stelts S, Taylor MH, Nappi J, Van Bakel AB.
    Ann Pharmacother; 2008 Jun; 42(6):904-5. PubMed ID: 18430794
    [No Abstract] [Full Text] [Related]

  • 4. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK.
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [Abstract] [Full Text] [Related]

  • 5. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H.
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [Abstract] [Full Text] [Related]

  • 6. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment.
    Bresci G, Parisi G, Capria A.
    Colorectal Dis; 2008 Oct; 10(8):814-7. PubMed ID: 18834420
    [Abstract] [Full Text] [Related]

  • 7. Vancomycin-induced drug hypersensitivity syndrome.
    Yazganoglu KD, Ozkaya E, Ergin-Ozcan P, Cakar N.
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):648-50. PubMed ID: 16164735
    [No Abstract] [Full Text] [Related]

  • 8. Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance.
    Soga K, Itani K.
    Clin J Gastroenterol; 2019 Dec; 12(6):578-582. PubMed ID: 31037567
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Salmonellosis and ulcerative colitis. A causal relationship or just a coincidence.
    Karaoglu AO, Yukselen V, Ertem GT, Erkus M.
    Saudi Med J; 2004 Oct; 25(10):1486-8. PubMed ID: 15494829
    [Abstract] [Full Text] [Related]

  • 11. Comment: Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis and the Kounis syndrome.
    Kounis GN, Kouni SA, Chiladakis JA, Kounis NG.
    Ann Pharmacother; 2009 Feb; 43(2):393-4. PubMed ID: 19141654
    [No Abstract] [Full Text] [Related]

  • 12. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 13. Pemphigus vulgaris and ulcerative colitis.
    Kacar S, Sezgin O, Sahin T.
    Am J Gastroenterol; 2002 Feb; 97(2):507-8. PubMed ID: 11866312
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Activity indices--objective criteria of the estimation of severity level of ulcerous colitis].
    Bakulin IG, Stanke DA, Belousova EA, Golovenko OV, Mikhailova TL.
    Eksp Klin Gastroenterol; 2008 Feb; (6):14-6. PubMed ID: 19334421
    [No Abstract] [Full Text] [Related]

  • 16. Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature.
    Sentongo TA, Piccoli DA.
    J Pediatr Gastroenterol Nutr; 1998 Sep; 27(3):344-7. PubMed ID: 9740210
    [No Abstract] [Full Text] [Related]

  • 17. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB.
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [Abstract] [Full Text] [Related]

  • 18. Peripheral T-cell lymphoma mimicking 5-aminosalicylate hypersensitivity in ulcerative colitis.
    Kong LM, Fok KC, Tsui A, Qian C, Fisher L.
    Intern Med J; 2013 Oct; 43(10):1137-40. PubMed ID: 24134170
    [Abstract] [Full Text] [Related]

  • 19. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease.
    Siegel CA.
    Gastroenterology; 2009 Dec; 137(6):1880-2. PubMed ID: 19879213
    [No Abstract] [Full Text] [Related]

  • 20. Mesalamine hypersensitivity and Kounis syndrome in a pediatric ulcerative colitis patient.
    Kounis GN, Kouni SA, Hahalis G, Kounis NG.
    World J Gastroenterol; 2008 Dec 14; 14(46):7141-2. PubMed ID: 19084925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.